Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review

State‐of‐the‐art treatment of systemic lupus erythematosus

(2020) Yoshiya Tanaka   International Journal of Rheumatic Diseases

Histologic comparison of tumor necrosis factor-α inhibitor–induced psoriasis and psoriasis vulgaris

(2020) Jeffrey Zhu Hu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review

(2020) A. Al‐Janabi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Drug‐induced vitiligo: a case/non‐case study in Vigibase ® , the WHO pharmacovigilance database

(2020) Norah Anthony et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Assessing the incidence of skin and soft tissue infection in patients on biologics

(2020) Emily D. Nguyen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study

(2020) María-Laura Cossio et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy

(2020) Gaurav B. Nigam et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

(2020) William J Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus

(2020) Chrissy Bolton et al.   DRUGS IN R&D

Injection site reactions with the use of biological agents

(2019) Elena Thomaidou et al.   Dermatologic Therapy

Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders

(2019) Simone Garcovich et al.   Frontiers in Pharmacology

Successful treatment of refractory mechanic’s hands with ustekinumab in a patient with the antisynthetase syndrome

(2019) Iago Pinal-Fernandez et al.   RHEUMATOLOGY

Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: A single-center retrospective study

(2019) Khaled Ezzedine et al.   JOURNAL OF DERMATOLOGY

Safety of drugs used for the treatment of Crohn’s disease

(2019) Aviv Pudipeddi et al.   Expert Opinion On Drug Safety

Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review

(2019) Thomas Chateau et al.   Journal of Crohns & Colitis

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

(2019) William J. Sandborn et al.   GASTROENTEROLOGY

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-Marketing Data

(2019) Russell D Cohen et al.   Journal of Crohns & Colitis

The first case of natalizumab-induced subacute cutaenous lupus erythematosus

(2019) Chrissy Bolton et al.   RHEUMATOLOGY

Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study

(2019) Viktor Wintzell et al.   Lancet Gastroenterology & Hepatology

Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients

(2018) Alyce Anderson et al.   DIGESTIVE DISEASES AND SCIENCES

Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy

(2018) Shilpa Sridhar et al.   INFLAMMATORY BOWEL DISEASES

Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study

(2018) Jung Min Bae et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience

(2018) Paul Sator   Therapeutic Advances in Chronic Disease

Malignancies in Inflammatory Bowel Disease

(2018) Sylvie Scharl et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: a systematic review and meta-analysis

(2018) Mathurin Fumery et al.   DIGESTIVE AND LIVER DISEASE

Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015

(2017) Toshinobu Matsui et al.   International Journal of Medical Sciences

A Rare Case of Amyopathic Juvenile Dermatomyositis Associated With Psoriasis Successfully Treated With Ustekinumab

(2017) Claudia L. Montoya et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective

(2017) Farah Succaria et al.   JOURNAL OF DERMATOLOGY

Disease-related and drug-induced skin manifestations in inflammatory bowel disease

(2017) Pieter Hindryckx et al.   Expert Review of Gastroenterology & Hepatology

Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects

(2016) Philippe A.R.R. Pijls et al.   DIGESTIVE AND LIVER DISEASE

Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort

(2016) Tim R.A. van den Heuvel et al.   INTERNATIONAL JOURNAL OF CANCER

Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism

(2016) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review

(2016) Mio Nakamura et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Increased Cumulative Incidence of Dermatomyositis in Ulcerative Colitis: a Nationwide Cohort Study

(2016) Chia-Chun Tseng et al.   Scientific Reports

Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study

(2015) D. Pugliese et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Cumulative Incidence of, Risk Factors for and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience

(2015) Estelle Fréling et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Alopecia secondary to anti-tumor necrosis factor-alpha therapy

(2015) Lara Beatriz Prata Ribeiro et al.   ANAIS BRASILEIROS DE DERMATOLOGIA

Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease

(2015) Isabelle Cleynen et al.   ANNALS OF INTERNAL MEDICINE

Granulomatous Drug Eruptions

(2015) Roni P. Dodiuk-Gad et al.   DERMATOLOGIC CLINICS

Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease

(2015) M. Severs et al.   Journal of Crohns & Colitis

The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease

(2015) Marcus Harbord et al.   Journal of Crohns & Colitis

Association between tumour necrosis factor-  inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study

(2015) N. Nyboe Andersen et al.   BMJ-British Medical Journal

Association between tumour necrosis factor-  inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study

(2015) N. Nyboe Andersen et al.   BMJ-British Medical Journal

Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease

(2014) Nynne Nyboe Andersen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

New Onset of Dermatomyositis/Polymyositis during Anti-TNF-αTherapies: A Systematic Literature Review

(2014) Alexandra Maria Giovanna Brunasso et al.   TheScientificWorldJOURNAL

Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease

(2012) Millie D. Long et al.   GASTROENTEROLOGY

Skin Manifestations of Inflammatory Bowel Disease

(2012) Brian L. Huang et al.   Frontiers in Physiology

Pelade au cours d’un traitement par anti-TNF alpha : neuf cas

(2011) E. Le Bidre et al.   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

Netting Neutrophils Are Major Inducers of Type I IFN Production in Pediatric Systemic Lupus Erythematosus

(2011) G. S. Garcia-Romo et al.   Science Translational Medicine

Adverse Cutaneous Reactions Induced by TNF-α Antagonist Therapy

(2011) Joaquín Borrás-Blasco et al.   SOUTHERN MEDICAL JOURNAL

Histopathologic Spectrum of Psoriasiform Skin Reactions Associated With Tumor Necrosis Factor-α Inhibitor Therapy. A Study of 16 Biopsies

(2010) Alvaro C Laga et al.   AMERICAN JOURNAL OF DERMATOPATHOLOGY

Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy

(2010) J. M. Ramos et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Dermatological complications and safety of anti-TNF treatments

(2009) J. F. Kerbleski et al.   GUT

Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical review

(2009) Aikaterini-Evaggelia Moustou et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Lichen planus–like eruptions: An emerging side effect of tumor necrosis factor-α antagonists

(2009) Adam Asarch et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Erythema multiforme during anti–tumor necrosis factor treatment for plaque psoriasis

(2009) Jennifer Ahdout et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY